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Abstract 
Background Stroke is a leading cause of morbidity and mortality, and its incidence 
increases with age. Both in animals and humans, oxidative stress appears to play an 
important role in ischemic stroke, with or without reperfusion. The adaptor protein 
p66Shc is a key regulator of reactive oxygen species (ROS) production, and a 
mediator of ischemia/reperfusion damage in ex-vivo hearts. Hence, we hypothesised 
that p66Shc may be involved in ischemia/reperfusion brain damage. To this end, we 
investigated whether genetic deletion of p66Shc protects from ischemia/reperfusion 
brain injury.   
Methods and Results Transient middle cerebral artery occlusion (MCAO) was 
performed to induce ischemia/reperfusion brain injury in wild type (Wt) and p66Shc 
knockout mice (p66Shc-/-), followed by 24 h of reperfusion. Cerebral blood flow (CBF) 
and blood pressure measurements revealed comparable hemodynamics in both 
experimental groups. Neuronal nuclear antigen (NeuN) immunohistochemical 
staining showed a significantly reduced stroke size in p66Shc-/- as compared to Wt 
mice (P<0.05, n=7-8). In line with this, p66Shc-/- mice exhibited a less impaired 
neurological function and a decreased production of free radicals locally and 
systemically (P<0.05, n=4-5). Following MCAO, protein levels of gp91phox NADPH 
oxidase subunit, was increased in brain homogenates of Wt (P<0.05, n=4), but not of 
p66Shc-/- mice. Further, reperfusion injury in Wt mice induced p66Shc protein in the 
basilar and middle cerebral artery, but not in brain tissue suggesting a predominant 
involvement of vascular p66Shc.  
Conclusion In the present study we show that deletion of the aging gene p66Shc 
protects mice from ischemia/reperfusion brain injury through a blunted production of 
free radicals. The ROS mediator p66Shc may represent a novel therapeutical target 
for the treatment of ischemic stroke. 
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Introduction 
Stroke is a leading global cause of mortality, responsible for more deaths than 
cancer1. Even in patients presenting comparable degrees of ischemia, a huge 
variability in the recovery of brain function is observed indicating a complex 
pathological process which to date, still lacks a specific therapy for its effective 
treatment2. Indeed, even reopening of the stroke-related artery with either 
thrombolysis or catheter intervention, is still far from providing a safe and effective 
therapy for the majority of patients. It thus appears crucial to elucidate the molecular 
mechanisms underlying the pathogenesis of neuronal injury after stroke to set the 
basis for the design of novel effective therapeutical strategies. 
Reactive oxygen species (ROS) are considered as crucial players in cerebrovascular 
disease3, 4. Several animal and human studies showed an association between 
ischemic stroke and increased systemic and local production of ROS5-9. A large body 
of evidence indicates nicotinamide adenine dinucleotide phosphate oxidase (NADPH 
oxidase) as a major source of ROS generation in cerebrovascular disease3, 10. In line 
with this, NADPH oxidase expression is profoundly greater in the vessel wall of 
cerebral rather than systemic arteries11 and its genetic deletion in mice reduces brain 
infarction12. Recently, NADPH oxidase has been shown to be a downstream target of 
the adaptor protein p66Shc 13.  
The mammalian p66Shc adaptor protein, together with p46Shc and p52Shc, belongs to 
ShcA adaptor/docking protein family which plays an important role in transducing 
activation signals from receptors, such as growth factor, cytokines, and integrins, to 
downstream signaling cascades14, 15. Among the three isoforms, p46Shc and p52Shc 
are important in the regulation of growth factor induced Ras/Erk signaling14, 15, 
whereas p66Shc is crucially involved in ROS generation and translates oxidative 
stress into apoptosis14. Genetic deletion of p66Shc in mice extends lifespan by 30%16, 
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and slows down the progression of atherogenesis in double mutant p66Shc-/-/ApoE-/- 
mice fed on a high fat diet17, 18. Deletion of p66Shc also protects from hyperglycemia-
induced endothelial dysfunction19, 20, reduces fat accumulation and premature death 
in adipose tissue 21, 22 and attenuates glomerulopathy23, 24 in diabetic mice. The 
reported protective effects achieved by p66Shc deletion are mainly due to reduced 
oxidative stress, improved insulin sensitization, increased mitochondrial uncoupling 
and reduced triglyceride accumulation17-19, 21-27. In line with this, increased levels of 
p66Shc mRNA have been reported in peripheral blood mononuclear cells of type-2 
diabetic patients25, and in patients with acute myocardial infarction28. Enhanced 
expression of p66Shc has been reported in ethanol-induced liver damage in mice29, 
chronic kidney dysfunction in spontaneous hypertension rats30 and aged rats30, and 
HIV-1 induced cell apoptosis in podocyte31, which is associated to a lower level of 
ROS production and a blunted activation of NFkappaB29, 30. Of note, deletion of 
p66Shc was also shown to protect ex vivo perfused murine hearts from 
ischemia/reperfusion-induced injury32; however the involvement of p66Shc in stroke is 
largely unknown. 
In the present study, we thus analyzed the effects of genetic deletion of p66Shc in 
ischemia/reperfusion brain injury. In particular, we investigated whether p66Shc 
knockout mice are protected from ischemia/reperfusion-induced and ROS-mediated 
brain injury and neurological deficits.  
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Material and Methods  
Animal model 
Experiments were performed on male, 12-14 weeks old wild type (C57Bl6J) and 
p66Shc knockout mice (p66Shc-/-). Animals were fed on a normal chow diet and had ad 
libitum access to food and water, and were maintained at 24o C under a 12 hours 
light/dark cycle. Study design and experimental protocols were approved by the 
institutional animal care committee (Licence Nr. TVA 139_2008; Kommission für 
Tierversuche des Kantons Zürich, Switzerland).  
 
Middle Cerebral Artery Occlusion Model and Hemodynamics Measurements 
To induce ischemia/reperfusion brain injury, a transient middle cerebral artery 
occlusion (MCAO) surgery was performed on both p66Shc-/- and wild type mice as 
previously described33. Mice were initially anesthetized with 4% of isoflurane and 
then maintained on 1.5% isofurane vaporized in NO2 and O2 (2:1). Following a 
midline cervical incision, the left common carotid artery (CCA), external (ECA) and 
internal carotid artery (ICA) were carefully exposed under an operating microscope. 
Thereafter, a 6-0 silicone-coated filament (Doccol Corporation, Redlands, USA) was 
introduced into the CCA and advanced into the ICA about 9-12 mm from the common 
carotid bifurcation. Rectal temperature was maintained at 37±0.5 ºC while the 
animals were under anesthesia through the use of circulating water pads. The thread 
was left in place for 60 min. After removal of the thread and wound care, animals 
were carefully observed and cared for and left in their cages for the next 24 hours. 
The same procedure was performed for sham-operated animals. However, silicone-
coated filament was advanced into the ICA about 5 mm from the common carotid 
bifurcation, without interruption of cerebral blood flow in the middle cerebral artery. 
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During anesthesia, regional cerebral blood flow (rCBF) in the area of the cortex 
supplied by the MCA was measured using laser Doppler flowmetry (PeriFluxSystem 
5000 with probe model no.418-1, Perimed AB, Jărfălla, Sweden). The microtip probe 
was positioned and glued approximately 2 mm posterior and 6 mm lateral to bregma.  
For blood pressure measurements, mice were allowed to familiarize with the 
procedure and equipment for a period of 1 week and then systolic (SBP) and diastolic 
blood pressure (DBP) and heart rate were recorded using the tail-cuff method (model 
LE 5002, Storage Pressure Meter, Letica, Spain).  
 MCAO experiments were performed blindly.  
 
Neurological Deficit Measurement  
Neurological deficit measurement was performed after 1 and 24 hours of reperfusion 
following MCAO, using a 4-point scale based on Bederson test34: Normal motor 
function was scored as 0, flexion of the contralateral torso and forelimb on lifting the 
animal by the tail as 1, circling to the contralateral side but normal posture at rest as 
2, leaning to the contralateral side at rest as 3, and no spontaneous motor activity as 
4. Neurological deficit measurements were performed by two people independently in 
a blinded way. 
 
Stroke Size Measurement 
Following 24 h of reperfusion, mice were sacrificed and perfused with PBS and 
relevant organs were excised. Brains were immersed in 4% formalin in phosphate 
buffer overnight and transferred to 30% sucrose solution for at least 3 days. Next, 
coronal 30-µm-thick sections were cut on a freezing microtome (Leica, Nussloch, 
 7
Germany). Stroke size was measured by immunohistochemical NeuN as previously 
performed (Dilution 1:100, Millipore, Temecula CA, USA)35. Quantification of stroke 
size was performed using NIH ImageJ software.   
 
Western Blotting 
Protein expression was determined by Western blot analysis. Isolated brains, basilar  
arteries, and middle cerebral arteries were homogenized in lysis buffer (NaCl 150 
mmol/L, EDTA 1 mmol/L, NaF 1 mmol/L, DTT 1 mmol/L, aprotinin 10 µg/µl, leupeptin 
10 µg/µl, Na3VO4 0.1 mmol/L, PMSF 1 mmol/L, and NP-40 0.5%). Protein 
concentration was measured according to the manufacturer’s recommendations (Bio-
Rad Laboratories GmbH, München, Germany). Equal amounts of protein were 
separated on a 10% SDS-PAGE, and transferred onto a polyvinylidene fluoride 
membrane (Millipore, Volketswil, Switzerland) by semidry transfer. Antibodies against 
gp91phox, p67phox and p47phox (all from Upstate) were used at 1:500 dilution. Anti-
Shc (Cell Signaling, Danvers, MA) was used at 1:1000 dilution. Blots were 
normalized to α-tubulin (1:20000 dilution, Sigma), or glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) expression (1:20000 dilution, Millipore, Temecula, CA). 
Anti-rabbit and anti-mouse secondary antibodies were purchased from GE 
Healthcare (Buckinghamshire, United Kingdom). For detection of protein 
carbonylation, dinitrophenol antibody (LifeSpan BioSciences, Inc.) at 1:200 dilution 
was used. All western blots were quantified by densitometric analysis performed by 
Scion Image Corporation software. 
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Measurement of ROS 
O2− production in whole blood was determined using the spin trap 1-hydroxy-3-
methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine (Noxygen, Germany). Blood 
samples were mixed with Krebs-HEPES solution containing sodium 
diethyldithiocarbamate trihydrate (5 μmol/L), deferoxamine methanesulfonate (25 
μmol/L), and 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine (200 
μmol/L) (all from Noxygen, Germany) and Heparin (100 U/ml). Samples were frozen 
in liquid nitrogen and O2− production was assessed with an ESR spectrometer 
(Bruker, Bremen, Germany) with the following instrumental settings: center field 
2.011 g, field sweep 100 G, microwave power 1 mW, modulation amplitude 10 G, 
sweep time 10.4 sec, number of scan 10. 
 
Statistical analysis 
Data are given as mean±SEM. Statistical analysis was done by two-way ANOVA 
analysis of variance with post hoc multiple comparisons using Bonferroni test, or 
paired/unpaired T-test in two way tails as appropriate. A probability value p<0.05 
denoted a significant difference. Statistical analyses were performed using GraphPad 
Prism software version 4.03 (GraphPad Software Inc., La Jolla, CA, USA).  
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Results 
Reduced brain infarction after ischemia/reperfusion injury in p66Shc-/- mice 
To evaluate the role of p66Shc in ischemia/reperfusion brain injury, a transient MCAO 
surgery was performed on both, p66Shc-/- and Wt mice, in order to induce a focal 
ischemic stroke. MCAO is a reliable and reproducible rodent model of cerebral 
ischemia in humans that has been demonstrated to result in sensorimotor and 
cognitive deficits33. Following 60 min of MCA occlusion, the silicone filament was 
withdrawn allowing reperfusion for 24 hrs.  Following 24 hours of reperfusion both 
p66Shc-/- (P<0.0001) and Wt (P=0.0086) mice underwent a comparable weight loss 
(data not shown). To quantify stroke size, NeuN immunohistochemical staining was 
performed as previously described35. Morphometrical analysis revealed a significantly 
reduced stroke size in p66Shc-/- mice compared to Wt mice (Wt: 42.84±6.05 mm2 vs. 
p66Shc-/-: 16.66±7.95 mm2; *P=0.0196; n=7-8; Figure 1A). Sham-operated Wt and 
p66Shc-/- did not display any lesions (data not shown). 
Genetic deletion of p66Shc improves neurological function following MCAO  
For the assessment of neurological function after MCAO we performed a Bederson-
based 4-point scale test. After 1 h of reperfusion, both, Wt and p66Shc-/- mice 
exhibited marked coordination dysfunction, shown as decreased activity, imbalance 
of movement, and decreased gripping ability (Wt: 1.87±0.26 vs. p66Shc-/-: 1.43±0.17; 
P=N.S.; n=14; Figure 1B). Following 24 h of reperfusion p66Shc-/- mice showed an 
improved neurological function compared to Wt mice (Wt: 1.53±0.19 vs. p66Shc-/-: 
0.89±0.33; *P=0.0142; n= 14; Figure 1B). Moreover, neurological deficit score of 
p66Shc-/- was improved at 24 h compared to 1 h of reperfusion (24 h: 0.89±0.33 vs. 1 
h: 1.43±0.17; #P=0.0130; n=14; Figure 1B); Such improvement was not observed in 
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Wt mice (24 h: 1.53±0.19 vs. 1 h: 1.87±0.26; P=0.2449; n=14; Figure 1B), suggesting 
an improved recovery potential in p66Shc-/- mice. Both Wt and p66Shc-/- sham operated 
mice, did not exhibit any neurological deficit at neither 1 nor 24 h (data not shown).  
Comparable cerebral perfusion and systemic blood pressure in Wt and p66Shc-/- 
mice  
Regional cerebral blood flow (rCBF) was recorded during MCAO procedure using 
laser Doppler flowmetry. Basal rCBF was comparable between Wt and p66Shc-/- mice. 
Following ligation of the CCA, a comparable reduction in blood flow was observed in 
both experimental groups (Wt: -49.6±2.69% vs. p66Shc-/-: -51.67±9.37%; Figure 2A); 
similarly, after insertion of the silicon thread to achieve MCAO, a comparable degree 
of rCBF reduction compared to basal level was recorded in Wt and p66Shc-/- mice 
indicating a comparable degree of MCA occlusion in both groups (Wt: -84.86±2.49% 
vs. p66Shc-/-: -86.13±2.77%; Figure 2A). Finally, upon retraction of the silicone thread 
a comparable re-establishment of blood flow was observed in both Wt and p66Shc-/- 
mice (Wt: 53.58±6.82% vs. p66Shc-/-: 48.41±11.41%; P=N.S. for all time points; n=6-7; 
Figure 2A). 
In order to exclude possible interference on stroke size by different systemic blood 
pressure in the 2 strains, blood pressure and heart rate were measured. No 
differences in systolic and diastolic blood pressure (SBP, DBP) as well as in heart 
rate were observed in both experimental groups (SBP: Wt: 154±9.866 mmHg vs. 
p66Shc-/-: 146.7±8.212 mmHg; P=N.S.; Figure 2B; DBP: Wt: 124±8.083 mmHg vs. 
p66Shc-/-: 128.7±7.219 mmHg; P=N.S.; Figure 2C; Heart rate: Wt: 508.3±3.930 bpm 
vs. p66Shc-/-: 518.7±3.283 bpm; P=N.S.; Figure 2D). 
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Ischemia/reperfusion injury-induced local and systemic oxidative stress is 
reduced in p66Shc-/- mice  
To address the role of oxidative stress, its level was quantified in whole brain 
homogenates after ischemia/reperfusion by measuring total protein carbonylation. 
Protein carbonylation is a widely accepted index of oxidative stress and the most 
common posttranslational protein modification induced by oxidative stress. 
Ischemia/reperfusion injury induced a significant increase in protein carbonylation in 
the brain of Wt stroke mice compared to that of sham operated Wt mice (Wt stroke: 
207.1±40.3% vs. Wt sham: 100%; *P<0.05; n=4; Figure 3A). By contrast, no change 
in brain oxidative stress levels after ischemia/reperfusion was observed in p66Shc-/- 
stroke mice as compared to shams (p66Shc-/- stroke: 99.62±14.48% vs. p66Shc-/- sham: 
72.77±18.17%; P=N.S.; n=3-5; Figure 3A).  
To determine levels of systemic oxidative stress following ischemia/reperfusion injury, 
O2- levels were measured in whole blood using electron spin resonance spectroscopy. 
Wt stroke mice showed increased ROS generation after 24 h of reperfusion 
compared to Wt sham mice (0.068±0.009 nmol vs. 0.032±0.005 nmol; *P<0.01; n=4-
6; Figure 3B). In contrast, p66Shc-/- stroke mice displayed comparable levels of ROS 
to p66Shc-/- sham mice (0.025±0.003 nmol vs. 0.043±0.009 nmol; P=N.S.; n=3-5; 
Figure 3B).  
Increased protein levels of gp91phox NADPH oxidase subunit in Wt mice after 
MCAO 
NADPH oxidase is a well known major source for ROS production in cerebrovascular 
disease as well as a downstream target of p66Shc; to this end, its expression was 
measured in brain homogenates 24 h after MCAO. In the present study, protein 
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expression of gp91phox NADPH oxidase subunits, but not of p67phox and p47phox, 
was significantly increased in the brain of Wt stroke mice compared to that of Wt 
sham mice (gp91phox: Wt stroke: 348±69.49% vs. Wt sham: 100%; *P<0.05; n=4; 
Figure 4A). Interestingly, this increase was not observed in the brain of p66Shc-/- 
stroke mice compared to that of p66Shc-/- sham ones (gp91phox: p66Shc-/- stroke: 
108.5±18.09% vs. p66Shc-/- sham: 50.14±11.73%; P=N.S.; n=3-5; Figure 4A). By 
contrast, p67phox (p67phox: Wt stroke: 427.1±139.1% vs. Wt sham: 100%; P=N.S.; 
n=3-5; Figure 4B) and p47phox (data not shown) NADPH oxidase subunit protein 
expression did not change in any of the experimental groups. 
To exclude possible involvement of other pro- anti-oxidant enzymes we looked at 
protein expression of COX-2, SOD1, SOD2 and Gpx and found no significant 
differences in the levels of these proteins in Wt stroke versus p66Shc-/- stroke groups 
(data not shown). 
Following ischemia/reperfusion p66Shc protein is increased in the basilar artery 
and middle cerebral artery but not in whole brain. 
To determine regulation of p66Shc expression in cerebral tissues following 
ischemia/reperfusion, western blotting analysis was performed. p66Shc protein 
expression in the basilar artery of Wt stroke mice was profoundly increased 
compared to wild type sham mice (Wt stroke: 615.4±257.1% vs. Wt sham: 
100±15.26%; *P=0.0245; n=7-8; Figure 5A). In line with this, p66Shc protein levels in 
the middle cerebral artery of Wt stroke mice were also elevated compared to wild 
type sham mice (Figure 5B). By sharp contrast, hardly any p66Shc expression was 
detected in whole brain homogenates and most importantly its levels remained 
unchanged after ischemia/reperfusion (Figure 5C). 
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Discussion  
The present study demonstrates for the first time that genetic deletion of the adaptor 
protein p66Shc-/- protects mice from ischemia/reperfusion-induced brain injury and 
consequent neurological deficits. This effect is paralleled by a blunted activation of 
the pro-oxidant enzyme NADPH oxidase, a downstream target of p66Shc, and a 
reduced production of free radicals.  
Transient occlusion of the middle cerebral artery is a well established model of 
stroke36. Indeed, in our study, this approach led to sizable strokes and a reproducible 
neurological deficit. Interestingly, genetic deletion of p66Shc protected mice from 
ischemia/reperfusion-induced brain injury. Following 1 h occlusion and 24 h of 
reperfusion, p66Shc-/- displayed an over 50% reduction in cortical and subcortical brain 
lesions as compared to Wt mice. Our findings expand a previous report showing that 
p66Shc deletion is protective against ischemia/reperfusion injury in ex-vivo perfused 
hearts32 to an in vivo setting on a different organ. Assessment of neurological deficit 
1 h after MCAO denoted a similar degree of impairment in both Wt and p66Shc-/- mice. 
However, following 24 h of reperfusion p66Shc-/- mice displayed a marked 
improvement in neuromotor function compared to Wt mice. This indicates that (1) the 
protective effects of p66Shc-/- deletion interfere primarily with reperfusion injury and not 
with the effects of ischemia and (2) that these effects lead to a better neurological 
recovery after brain reperfusion. In order to exclude a possible interference by 
different blood pressure values and/or different degree of occlusion-reperfusion, we 
measured blood pressure, heart rate as well as rCBF in all experimental groups. 
Indeed, all hemodynamic values were comparable in Wt and p66Shc-/- mice indicating 
that the observed effect is not the result of gross physiological or procedural 
differences. These findings are of potential clinical importance as reperfusion injury 
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with subsequent brain edema is an important complication after successful 
thrombolysis in patients presenting with ischemic stroke37, 38. Nevertheless, stroke 
size and neurological impairment were only examined at 24 hours; although early 
time points are crucial, showing a preserved protective effect at later time points 
would be important for future developments based on the herein reported data. 
Increased production of ROS is widely recognized as a key mediator of reperfusion-
induced brain injury2, 9, 39, 40, and protein carbonylation is an established marker of 
oxidative stress as well as the most common posttranslational protein modification 
induced by oxidative stress41, 42. Here, we report that Wt stroke mice show an 
increased carbonylation of brain proteins compared to Wt sham operated mice, 
demostrating that ischemia/reperfusion injury indeed induces oxidative stress5-8. In 
contrast, brain tissue of p66Shc-/- stroke mice did not display increased levels of 
protein carbonylation neither compared to p66Shc-/- shams nor to Wt shams, 
suggesting that p66Shc is crucially involved in this process. In light of the important 
role played by ROS in ischemia/reperfusion-induced brain injury39, 43, strategies 
aimed at preventing their increase following reperfusion are currently being sought 
for2, 39. Following ischemia, increased levels of ROS promote endothelial activation 
and increase the permeability of brain arteries leading to the expression of adhesion 
molecules, proinflammatory cytokines and increased leukocyte adhesion all of which 
are recognized mechanisms influencing stroke size40 39, 43. Indeed, p66Shc-/- stroke 
mice displayed a reduced generation of ROS and a reduced stroke size. In patients 
with ischemic stroke increased ROS levels have been measured also in circulating 
blood9. In line with this, we found increased levels of O2- in peripheral blood of Wt 
stroke mice, but not in p66Shc-/- stroke mice, suggesting a systemic activation of ROS 
producing pathways under these conditions.  Although oxidative stress is crucially 
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implicated in the pathogenesis of cerebrovascular disease, previous large clinical 
trials aimed at reducing ROS failed to improve outcome44, 45. Several factors could be 
taken into account to explain this failure: (i) High concentration of antioxidant 
supplements has been introduced in daily human diet due to significant improvement 
of healthcare (ii) endogenous antioxidant defense systems may be depressed by 
additional antioxidant treatment; (iii) exogenous antioxidant agent may function 
differently from endogenous ones; and (iv) intracellular ROS production sites may be 
sequestered in organelles (for instance mitochondria), thus preventing dietary 
antioxidants to reach their putative site of action46. Hence, the development of 
treatment strategies such as prevention of p66Shc activation to prevent increased 
ROS production, rather than lowering it, may represent a more effective alternative. 
 NADPH oxidase is a membrane-bound enzyme known to be expressed in cerebral 
arteries47, 48 and recognized as a major source of ROS production in cerebrovascular 
disease3, 10, 11. NADPH oxidase expression is known to increase in disease 
conditions such as ischemia49, 50 and its genetic deletion in mice was shown to 
reduce brain infarction12; furthermore, NADPH oxidase was recently reported to be a 
downstream target of p66Shc13. In line with the above, protein expression of gp91phox 
NADPH oxidase subunit, but not of p67phox and p47phox, was strongly increased 
following ischemia/reperfusion in the brain of Wt stroke mice. However, this increase 
was not observed in p66Shc-/- stroke mice supporting previous reports that p66Shc is 
an upstream regulator of NADPH oxidase and that the p66Shc/NADPH oxidase axis is 
crucial for ischemia/reperfusion-induced ROS13. To further support this associative 
finding, we also looked at protein expression of other anti- or pro-oxidant enzymes 
such as COX-2, SOD1, SOD2 and Gpx and found no significant differences in the 
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levels of these in Wt stroke and p66Shc-/- stroke groups (data not shown). Yet, the 
exact mechanisms linking p66Shc and NAPDH oxidase deserve further investigation. 
The mammalian ShcA adaptor protein is ubiquitously expressed51-54, however, p66Shc 
is hardly detectable in the central nervous system55-57, with exception of the 
developing brain57 and cultured rat neurons58. Indeed, in the present study, p66Shc 
protein expression was hardly detectable in whole brain homogenates. Moreover, 
whole brain p66Shc expression remained unchanged following ischemia/reperfusion 
suggesting a minor involvement of cerebral p66Shc. By sharp contrast, we found that 
the basilar artery and middle cerebral artery display higher levels of basal p66Shc 
expression as compared to whole brain. Furthermore, p66Shc expression in the 
basilar and middle cerebral artery were dramatically increased following 
ischemia/reperfusion, suggesting that cerebrovascular rather than neuronal p66Shc 
maybe an important mediator of ischemia/reperfusion brain injury. Our findings could 
be partially explained by previous reports indicating a pivotal role of the cerebral 
vasculature in determining stroke size. Indeed, following reperfusion, the endothelium 
of cerebral arteries is focally activated thereby promoting leukocytes leakage into the 
extracellular matrix and inflammation both of which are important mechanism 
determining neuronal damage36, 40. The crucial role of cerebral arteries in determining 
stroke size was also recently underscored by Ke-Jie et. al. who showed that 
vascular-specific deletion of PPAR increases stroke size in the mouse via an 
increased post-ischemic inflammation36.  In further support of our interpretation, is the 
fact that preserved endothelial function has been described as the most common 
mechanism protecting p66Shc-/- mice in several disease models including diabetes19, 
atherosclerosis18 and aging26, 59-61 where ROS are known to play an important role.   
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In summary, this study shows for the first time that genetic deletion of p66Shc strongly 
reduces stroke size following ischemia/reperfusion brain injury. In line with this, 
p66Shc-/- mice displayed a far milder neurological deficit following 
ischemia/reperfusion as compared to Wt. The observed protective effects are likely 
mediated by a reduced activation of the p66Shc target NADPH oxidase which leads to 
a decreased production of free radicals. Inhibition of this novel pathway may be a 
novel and effective therapeutic target in preventing reperfusion injury in patients 
presenting with ischemic stroke undergoing thrombolysis of interventional reperfusion 
therapy.  
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Study limitations 
There are some limitations that need to be acknowledged and addressed regarding 
the present study. First of all, the use of knock out animals does not completely 
exclude the possibility of some adaptive mechanisms of compensatory nature taking 
place over the course of their life. Secondly, the observed blunted activation of 
NAPDH subunits observed in p66Shc-/- stroke mice, needs to be investigated further to 
elucidate the pathways involved. Lastly, in order to fully support our conclusions with 
respect to possible clinical applications, future studies including later time points as 
well as larger animal models and human proof-of-principle experiments should be 
conducted.   
 
Perspectives 
Over the last century, an impressive increase in human life expectancy occurred, 
hence, also due to constant birth rates, the population is aging. With ascending age, 
the incidence of cerebrovascular diseases, such as stroke, sharply increases. 
Although stroke is a leading cause of morbidity and mortality to date, no effective 
therapeutical strategy exists. In the present study, we have shown for the first time 
that genetic deletion of p66Shc protects mice from ischemia/reperfusion brain injury 
through a blunted activation of NADPH oxidase and a reduced production of free 
radicals. Hence, p66Shc represents an interesting novel target to be investigated in 
the context of ischemic stroke and reperfusion injury. 
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Figure Legends 
Figure 1. Stroke size and neurological deficit measurement after 
ischemia/reperfusion brain injury. A, Representative NeuN immunohistochemical 
staining 24 h after MCAO in Wt and p66Shc-/- mice. Arrows indicate subcortical and 
cortical infarct components. p66Shc-/- mice show reduced stroke size compared to Wt 
mice, *P= 0.0196. Values are given as mm3. B, Bederson test. Neurological deficit 
was measured either at 1 h of reperfusion or at 24 h of reperfusion. p66Shc-/- stroke 
mice show improved neurological function at 24 h of reperfusion compared to Wt 
stroke mice and to p66Shc-/- stroke mice at 1 h of reperfusion. *P=0.0142 for Wt stroke 
(24 h) vs. p66Shc-/- stroke mice (24 h). #P=0.0130 for p66Shc-/- stroke (24 h) vs. p66Shc-
/- stroke (1 h).   
Figure 2. Cerebral blood flow and arterial blood pressure measurements. A, Laser 
Doppler measurements revealed no difference in regional cerebral blood flow pre-
MCAO between wild type and p66Shc-/- mice and show a similar alteration upon MCA 
occlusion and reperfusion. B,C,D, Wild type and p66Shc-/- mice do not differ in systolic 
and diastolic blood pressure (SBP, DBP) as well as in heart rate.   
Figure 3. Production of free radicals locally (brain) and systemically (in whole blood). 
A, Wt mice, but not p66Shc-/- mice, show increased brain protein carbonylation after 
ischemia/reperfusion brain injury. Values are given as % of Wt sham operated mice. * 
P<0.05 for Wt stroke vs. Wt sham. B, Electron spin resonance spectroscopy 
measured increased O2- levels in whole blood of Wt stroke mice but not in p66Shc-/-. 
Values are given as nmol O2-. * P<0.05 for Wt stroke vs. Wt sham.  
Figure 4. Protein levels of NADPH oxidase subunits in whole brain homogenates. 
Western blotting reveals increased protein expression of gp91phox NADPH oxidase 
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subunit in brain homogenates of Wt stroke mice, but not of p66Shc-/- (A). In contrast, 
p67phox NADPH oxidase subunit expression does not change in any of the 
experimental groups (B). Values are given as % of Wt sham. * P<0.05 for Wt stroke 
vs. Wt sham. 
Figure 5. p66Shc protein levels in basilar artery, middle cerebral artery and brain. A,B, 
p66Shc protein expression is increased in basilar artery and middle cerebral artery of 
Wt stroke mice compared to Wt sham mice. C, Protein level of p66Shc in whole brain 
homogenates is hardly detectable and remains comparable between Wt stroke and 
Wt sham mice. Values are given as % of Wt sham mice. * P=0.0245 for Wt stroke vs. 
Wt sham. 
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